|(2R,3R,5S)-2-(6-氨基-9H-嘌呤-9-基)-5-(羟甲基)四氢呋喃-3-醇|CsnPharm

CAS No.: 73-03-0

虫草素 Catalog No. CSN10693

Synonyms: 虫草素;3'-Deoxyadenosine

Cordycepin is a nucleoside adenosine derivative that acts as an anticancer and antifungal agent. Cordycepin inhibits growth of various tumor cells in vitro. It can be converted to 3'-deoxyadenosine triphosphate (3'-dATP), which inhibits ATP-dependent DNA synthesis. Cordycepin is also useful for the study of messenger RNA transcription.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Cordycepin (3'-deoxyadenosine), a bioactive compound of Cordyceps militaris, has been shown to exhibit many pharmacological activities, such as anti-cancer, anti-inflammatory and anti-infection activities. Cordycepin is a potent inhibitor of IL-1beta-induced chemokine production and MMP expression and strongly blocks the p38/JNK/AP-1 signalling pathway in RASFs(RA synovial fibroblasts) ^[3]. Co-use of cordycepin and deoxycoformycin, an inhibitor of adenosine deaminase (ADD), more efficiently kills M. bovis and M. tuberculosis. The add-deleted mycobacterium is more sensitive to cordycepin^[4]. Cordycepin can induce apoptosis, resist cell cycle and cause DNA damage in cancer cells, and thus kill or control cancer cell growth. Also cordycepin can induce autophagy and modulate immune system. Furthermore, cordycepin also inhibits tumor metastasis^[5]. Cordycepin inhibited the nuclear translocation of P65 by preventing p‑IκBα(NF‑κB inhibitor α) activation; this resulted in the downregulation of CXCR4 (C‑X‑C chemokine receptor type 4) expression, and subsequently, in the impaired migration and invasion abilities of liver cancer cells and attenuated reactivity to SDF1(stromal cell‑derived factor 1) ^[6].
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00667329	Lymphoma	Phase 1	Active, not recruiting	July 2019	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse <<
NCT00483067	Leukemia	Phase 2	Completed	-	United States, Texas ... more >> U.T.M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Collapse <<
NCT00412594	Leukemia	Phase 2	Recruiting	June 2019	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Collapse <<

更多
参考文献

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 3.9802 mL
- 19.9011 mL
- 39.8023 mL
- 5 mM
- 0.7960 mL
- 3.9802 mL
- 7.9605 mL
- 10 mM
- 0.3980 mL
- 1.9901 mL
- 3.9802 mL

技术信息

CAS号

73-03-0

储存条件

粉末: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C10H13N5O3

运输

蓝冰

分子量

251.24

别名

虫草素;3'-Deoxyadenosine

溶解度

DMSO	49.0 mg/mL (195.0 mM)
Water	23.0 mg/mL (91.5 mM)
Ethanol	1.0 mg/mL (4.0 mM)

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00667329	Lymphoma	Phase 1	Active, not recruiting	July 2019	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse <<
NCT00483067	Leukemia	Phase 2	Completed	-	United States, Texas ... more >> U.T.M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Collapse <<
NCT00412594	Leukemia	Phase 2	Recruiting	June 2019	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Collapse <<
NCT00656812	Lymphoma of Mucosa-Associated ... more >>Lymphoid Tissue Collapse <<	Phase 2	Completed	-	Austria ... more >> Universitätsklinikum Graz Graz, Austria, A-8036 Universitaetsklinik Innsbruck/ Klinik für Innere Medizin Innsbruck, Austria, A-6020 Krankenhaus der Stadt Linz Linz, Austria, A-4020 Universitaetsklinik f. Innere Medizin III Salzburg, Austria, A-5020 AKH Wien / Universitaetsklinik fuer Innere Medizin I Vienna, Austria, A-1090 Collapse <<
NCT02157181	Hairy Cell Leukemia (HCL)	Phase 2	Completed	-	Germany ... more >> Community based hemato-oncology medical office Ansbach, Germany, 91522 Community based hemato-oncology medical office Aschaffenburg, Germany, 63739 Community based hemato-oncology medical office Celle, Germany, 29221 St.-Johannes-Hospital Dortmund, Germany, 44137 Städtische Kliniken Esslingen Esslingen, Germany, 73728 Universitätsklinik Frankfurt Frankfurt am Main, Germany, 60596 Universitätsklinik Freiburg Freiburg, Germany, 79106 Community based hemato-oncology medical office Fürth, Germany, 90766 University Clinic \| Med. Cinic IV Justus-Liebig-University Gießen, Germany, 3592 Wilhelm-Anton-Hospital Goch, Germany, 47574 Kath. Krankenhaus Hagen gem. GmbH Hagen, Germany, 58095 Community based hemato-oncology medical office Halle, Germany, 06108 Community based hemato-oncology medical office Hamburg, Germany, 21073 Meditinische Hochschule (MHH) Hannover, Germany, 30623 Community based hemato-oncology medical office Heidelberg, Germany, 69115 Marienhospital Herne/ Klinikum der Ruhr-Universität Bochum Herne, Germany, 44625 Community based hemato-oncology medical office Hilden, Germany, 40721 Community based hemato-oncology medical office Hildesheim, Germany, 31134 Klinikum Idar-Oberstein Idar-Oberstein, Germany, 55743 Community based hemato-oncology medical office Jena, Germany, 07743 Community based hemato-oncology medical office Kassel, Germany, 34125 Community based hemato-oncology medical office Kiel, Germany, 24105 Community based hemato-oncology medical office Koblenz, Germany, 56068 Community based hemato-oncology medical office Kronach, Germany, 96317 Community based hemato-oncology medical office Leer, Germany, 26789 Community based hemato-oncology medical office Leipzig, Germany, 04103 Städtische Kliniken Leverkusen, Germany, 51375 Community based hemato-oncology medical office Magdeburg, Germany, 39104 Community based hemato-oncology medical office Marburg, Germany, 35037 Klinik Schwäbisch Gmünd / Staufer Klinik Mutlangen, Germany, 73557 Community based hemato-oncology medical office München, Germany, 80335 Community based hemato-oncology medical office München, Germany, 81241 Klinikum Großhadern München, Germany, 81377 Community based hemato-oncology medical office Neunkirchen, Germany, 66538 Community based hemato-oncology medical office Neuwied, Germany, 56564 Community based hemato-oncology medical office Niddatal, Germany, 61194 Community based hemato-oncology medical office Nürnberg, Germany, 90449 MVZ Klinikum Osnabrück Osnabrück, Germany, 49076 Community based hemato-oncology medical office Pforzheim, Germany, 75179 Klinikum Ernst von Bergmann gGmbH Potsdam, Germany, 14467 St. Josefs-Krankenhaus Potsdam, Germany, 14471 Community based hemato-oncology medical office Schweinfurt, Germany, 97421 St. Marien-Krankenhaus Siegen, Germany, 57072 Community based hemato-oncology medical office Straubing, Germany, 94315 Diakonie-Klinikum Stuttgart Stuttgart, Germany, 70176 Community based hemato-oncology medical office Villingen, Germany, 78050 Community based hemato-oncology medical office Wolfsburg, Germany, 38440 Collapse <<
NCT00709215	Refractory TdT-Positive Leukem... more >>ia Collapse <<	Phase 1 Phase 2	Unknown	December 2010	United States, Massachusetts ... more >> Brigham & Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Daniel J DeAngelo, MD, PhD. 617-632-2645 Daniel_Deangelo@dfci.harvard.edu Principal Investigator: Daneil J DeAngelo, MD, PhD. Sub-Investigator: Richard Stone, MD Sub-Investigator: L. Andres Sirulnik, MD Sub-Investigator: Martha Wadleigh, MD Sub-Investigator: Gregory Abel, MD, MPH Sub-Investigator: Susan L Buchanan, PA Sub-Investigator: Adriana Penicaud, PA Sub-Investigator: Ilene Galinsky, APRN Sub-Investigator: Eyal Attar, MD Sub-Investigator: Philip Amrein, MD Sub-Investigator: Karen Kuhn Ballen, MD United States, Texas Cancer Therapy Reasearch Center at UTHSCA Recruiting San Antonio, Texas, United States, 78229 Contact: Swaminathan Padmanabhan, MD 210-450-5094 PadmanabhanS@uthscsa.edu Sub-Investigator: Monica Mita, MD Principal Investigator: Alain Mita, MD Collapse <<
NCT00003005	Leukemia	Phase 1	Completed	-	United States, District of Col... more >>umbia Vincent T. Lombardi Cancer Research Center, Georgetown University Washington, District of Columbia, United States, 20007 United States, Maryland Johns Hopkins Oncology Center Baltimore, Maryland, United States, 21287 United States, Massachusetts New England Medical Center Hospital Boston, Massachusetts, United States, 02111 Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Boston Medical Center Boston, Massachusetts, United States, 02118 University of Massachusetts Memorial Medical Center Worcester, Massachusetts, United States, 01655 United States, Missouri Washington University Barnard Cancer Center Saint Louis, Missouri, United States, 63110 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263-0001 United States, North Carolina Lineberger Comprehensive Cancer Center, UNC Chapel Hill, North Carolina, United States, 27599-7295 United States, Ohio Arthur G. James Cancer Hospital - Ohio State University Columbus, Ohio, United States, 43210 United States, Oregon Oregon Cancer Center at Oregon Health Sciences University Portland, Oregon, United States, 97201-3098 Collapse <<

虫草素 Catalog No. CSN10693

靶点选择性

请登录您的专属账户

确认信息